Biologic switching in allergic bronchopulmonary aspergillosis: a scoping review of published clinical experience Authors: Qiurong Hu, Xuanyu Pan, Ruchong Chen, Ganlu Li, Yixuan Li, Yu Zheng, Ziyang Zhong, Xinyi Zhang, Yuhang Chen, Jiazhen Ye, Jielin Duan, Jing Li Published: 2026 ABSTRACT AbstractBackgroundAllergic bronchopulmonary aspergillosis (ABPA) is a type 2 (T2) inflammatory pulmonary disorder with limited long-term treatment options. Although biologic therapies targeting T2 inflammation are increasingly used off-label in ABPA, clinical responses are heterogeneous, and some patients require switching between biologic agents. Evidence on biologic switching in ABPA, however, has not been systematically summarized.MethodsWe conducted a scoping review following PRISMA-ScR guidelines. PubMed, Embase, and Web of Science were searched from inception to 30 July 2025. Eligible studies included ABPA patients treated with biologics who underwent at least one documented biologic switch. Data on patient characteristics, biologic agents, reasons for switching, switching patterns, and reported clinical outcomes were extracted and summarized.ResultsThirty-one publications were included, comprising 2 retrospective observational studies, 3 case series, and 26 case reports or letters, describing 73 patients with ABPA and 108 biologic switching events. Omalizumab was the most commonly used first-line biologic. The most frequent initial switching pathway was from omalizumab to anti-interleukin (IL)-5/IL-5 receptor agents, while subsequent switching from anti-IL-5/IL-5 receptor therapy to dupilumab was commonly reported. Inadequate clinical response and adverse events were the leading reasons for switching. Across studies, biologic switching was frequently associated with reported clinical improvement, although outcome definitions and follow-up durations varied substantially.ConclusionsBiologic switching is a commonly reported strategy in ABPA management, particularly in patients with inadequate response or intolerance to initial therapy. However, available evidence is largely descriptive and case-based, precluding conclusions regarding comparative efficacy or optimal sequencing. Prospective studies are needed to guide biologic selection and switching in ABPA.Keywords: Allergic bronchopulmonary aspergillosis (ABPA), biologic therapy, biologic switching, type 2 inflammation (T2 inflammation), scoping review Highlight box Key findings • Biologic switching is a common and clinically significant strategy for managing allergic bronchopulmonary aspergillosis (ABPA), particularly for patients with inadequate response or intolerance to initial biologic therapy. What is known and what is new? • Biologic therapies targeting type 2 inflammation are increasingly used off-label in ABPA, but responses are heterogeneous. • This study systematically maps the published clinical experience of biologic switching in ABPA, highlighting the common sequences, reasons for transition, and overall favorable clinical outcomes. What is the implication, and what should change now? • Biologic switching offers a pragmatic management strategy for refractory ABPA. Prospective comparative trials are needed to define optimal sequencing and selection. Introduction Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated pulmonary disorder caused by an exaggerated hypersensitivity response to Aspergillus species, most commonly Aspergillus fumigatus, with other clinically relevant species including A. flavus, A. terreus, A. niger, and A. nidulans (1). It occurs predominantly in patients with asthma and cystic fibrosis (CF), and may also be observed in other chronic airway diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis (2); its development reflects a multifactorial process involving individual susceptibility, underlying airway diseases, fungal characteristics, and complex pathogen-host interactions. ABPA is characterized by a type 2 (T2) inflammatory response, in which inhaled fungal antigens activate airway epithelial and innate immune cells, leading to release of interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin (TSLP). These cytokines promote T helper 2 (Th2) and T2 innate lymphoid cell activation, resulting in IL-4, IL-5, and IL-13 production, immunoglobulin E (IgE) synthesis, eosinophilic inflammation, mucus plugging, and airway injury (3,4). The therapeutic goals of ABPA include reducing acute exacerbations, controlling airway inflammation, decreasing fungal burden, and preventing or delaying structural airway damage (1). Oral corticosteroids (OCS), most commonly prednisolone/prednisone, remain the first-line therapy for ABPA. Treatment is typically initiated at a moderate dose (e.g., 0.5 mg/kg/day) followed by gradual tapering over several months; alternative regimens and other agents such as methylprednisolone may also be used. However, the use of OCS is associated with a range of adverse effects such as osteoporosis and hyperglycemia, particularly with long-term use. Antifungal agents may reduce fungal burden. Recommended antifungal agents for ABPA mainly include triazoles such as itraconazole, voriconazole, posaconazole, and isavuconazole, as well as inhaled amphotericin B formulations (nebulised amphotericin B deoxycholate and nebulised liposomal amphotericin B) (5,6). Itraconazole and voriconazole are the most commonly used agents but require attention to hepatotoxicity, significant pharmacokinetic variability necessitating therapeutic drug monitoring, and clinically relevant drug-drug interactions mediated via the cytochrome P450 system. Posaconazole, isavuconazole, and nebulised amphotericin B may serve as alternative options in selected cases, but current evidence for their use remains limited. In addition, azole resistance in Aspergillus species remains an important clinical concern (7). Consequently, a subset of patients develops treatment-dependent ABPA, for whom effective long-term management options remain limited (8). Biologic therapies targeting key T2 inflammatory pathways have emerged as promising off-label treatments for ABPA (9-12). Approved biologics for asthma and related T2 inflammatory diseases include anti-IgE (omalizumab), anti-IL-4 receptor α (dupilumab), anti-IL-5 (mepolizumab and reslizumab), and anti-IL-5 receptor (benralizumab) and anti-TSLP therapy (tezepelumab) (13). Our previous meta-analysis demonstrated that omalizumab had the most robust evidence base in ABPA, while evidence for other biologics was largely derived from case series and case reports (14). In 2024, the International Society for Human and Animal Mycology (ISHAM)-ABPA Working Group published updated recommendations on the management of ABPA, in which oral glucocorticoids or itraconazole are recommended as initial therapy for acute ABPA, while biologic therapy is reserved for patients with treatment-dependent ABPA (1). Despite increasing use of biologics, treatment responses in ABPA remain heterogeneous, and some patients experience inadequate efficacy or intolerance requiring biologic switching (15). However, evidence on biologic switching in ABPA is fragmented and largely limited to isolated reports. Therefore, this scoping review aimed to systematically summarize published cases of biologic switching in ABPA, focusing on indications for switching, biologic agents used, and reported clinical outcomes. We present this article in accordance with the PRISMA-ScR reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0641/rc) (16). Methods Literature search strategy A systematic literature search was conducted using PubMed, Embase, and Web of Science from database inception to 30 July 2025. Although the search was conducted from inception, the ISHAM-ABPA [2024] criteria were applied during the screening phase to ensure the evidence aligns with the most recent diagnostic standards. Title and abstract searches were performed using the following strategy: (omalizumab OR dupilumab OR mepolizumab OR benralizumab OR reslizumab OR tezepelumab) AND ((Allergic Bronchopulmonary Aspergillosis) OR (Allergic Bronchopulmonary Mycosis) OR ABPA OR ABPM) AND (1900[Date - Publication]: 2025/07/30[Date - Publication]). Study selection Two investigators independently screened full-text articles. Discrepancies were resolved through discussion or adjudication by a third reviewer. Studies were included if they met the following criteria: (I) patients with a confirmed diagnosis of ABPA; (II) treatment with biologic agents with at least one documented biologic switch. Biologic switching was defined as discontinuation of one biologic agent followed by initiation of a different biologic, either sequentially or after a washout period; (III) publication types including case reports, case series, conference abstracts or posters, letters to the editor, retrospective studies, or clinical trials; (IV) language in English. Studies were excluded if they involved animal experiments or in vitro studies, duplicate publications, or if individual patient treatment courses or detailed biologic therapy information were not reported. The study selection process is summarized in a PRISMA flow diagram (Figure 1). Flow chart of study selection and screening process. ABPA, allergic bronchopulmonary aspergillosis. Data extraction During study selection and data extraction, the following key information was collected for individual case reports: baseline patient characteristics (including age, sex, and underlying conditions such as asthma or CF), initial biologic agent, treatment duration and response, reasons for switching (e.g., inadequate efficacy, adverse events, adherence issues, or economic factors), biologic agents used after switching, post-switch clinical response and adverse events, follow-up duration, and final clinical outcomes. For observational studies and case series, data extracted included study design, follow-up duration, number of participants, variables analyzed, interventions, outcomes, and main results. Results Study selection and characteristics A total of 634 records were identified through database searching. After applying inclusion criteria and full-text screening, 39 articles were assessed for eligibility. Studies were excluded for the following reasons: non-ABPA diagnosis (n=1), duplicate case reporting (n=1), concomitant use of dual biologic agents (n=4), and insufficient reporting of biologic treatment details (n=2). Ultimately, 31 publications published up to 30 July 2025 were included in this scoping review, comprising 2 retrospective observational studies, 3 case series (one conference abstract), and 26 case reports or letters (11 conference abstracts). Retrospective observational studies Two retrospective studies investigated published clinical reports use of biologic agents in patients with ABPA and together reported 37 patients who underwent biologic switching [10 cases reported by Lamothe et al. (17) and 27 cases by Carter et al. (15)]. Detailed information on switching sequences, treatment duration, reasons for discontinuation, and reported clinical outcomes is summarized in Table 1. Table 1Therapeutic details reported in retrospective studies of patients with ABPA included in this scoping reviewStudyDesignCase numberFirst-lineSecond-lineThird-lineFourth-lineBiologicsDuration (months)Reason for switchBiologicsDuration (months)Outcome/reason for switch†BiologicsDuration (months)Outcome/reason for switch†BiologicsDuration (months)OutcomeLamothe, Pedro A et al. (17)Retrospective study, article1Omalizumab114Failed treatment: no response + AEMepolizumab13–14Failed treatment: No response + AEBenralizumab7–8Failed treatment: No response + AEDupilumab42Responded2Omalizumab18Failed treatment: no response + AEMepolizumab29Failed treatment: AEDupilumab42Responded3Omalizumab2Failed treatment: AEBenralizumab12NRDupilumab31Responded4Mepolizumab3–4NRDupilumab5NRBenralizumab14–15Responded5Benralizumab9Failed treatment: no response + AEDupilumab36Responded6Mepolizumab7Failed treatment: AEDupilumab43Responded7Mepolizumab26Failed treatment: AEDupilumab32Responded8Mepolizumab17Failed treatment: no response + AEDupilumab58Responded9Omalizumab11Failed treatment: no response + AEDupilumab29Responded10Omalizumab11Failed treatment: AEMepolizumab55RespondedCarter, C et al. (15)Retrospective study, article1OmalizumabNRNo responseMepolizumabNRNo responseDupilumabNRResponded2BenralizumabNRIncreased infectionsMepolizumabNRResponded3DupilumabNRNo responseTezepelumabNRResponded4BenralizumabNRNo responseDupilumabNRResponded5MepolizumabNRHair lossBenralizumabNRResponded6MepolizumabNRNo responseReslizumabNRNo responseDupilumabNRResponded7MepolizumabNRResponded but stop due to infectionsBenralizumabNRNo responseDupilumabNRResponded8ReslizumabNRNo responseMepolizumabNRSide effectsDupilumabNRRashBenralizumabNRResponded9MepolizumabNRNo responseBenralizumabNRNo responseTezepelumabNRResponded10MepolizumabNRNo responseBenralizumabNRNo responseOmalizumabNRNo responseReslizumabNRResponded11MepolizumabNRNo responseBenralizumabNRResponded but stop due to malignancyStop biologic therapy12MepolizumabNRNo responseBenralizumabNRUnable to access responseStop biologic therapy13OmalizumabNRNo responseMepolizumabNRResponded14MepolizumabNRMental health issuesBenralizumabNRNo responseOmalizumabNRNo responseStop biologic therapy15MepolizumabNRSide effectsReslizumabNRNo responseBenralizumabNRNo responseStop biologic therapy16OmalizumabNRRashMepolizumabNRNo responseDupilumabNRResponded17MepolizumabNRNo responseBenralizumabNRNo responseStop biologic therapy18OmalizumabNRNo responseMepolizumabNRResponded19MepolizumabNRVariable responseBenralizumabNRResponded20OmalizumabNRNo responseBenralizumabNRNo responseDupilumabNRResponded21OmalizumabNRNo responseMepolizumabNRNo responseBenralizumabNRResponded22OmalizumabNRNo responseBenralizumabNRResponded23OmalizumabNRResponded but stop due to polymyositisMepolizumabNRResponded24OmalizumabNRNo responseTezepelumabNRVariable response25OmalizumabNRNo responseMepolizumabNRNo responseStop biologic therapy26OmalizumabNRNo responseTezepelumabNRResponded27OmalizumabNRNo responseMepolizumabNRNo responseStop biologic therapy†, interpreted as “reason for switch” if switching to another biologic; otherwise, interpreted as “outcome”. ABPA, allergic bronchopulmonary aspergillosis; AE, acute exacerbation; NR, not reported. Therapeutic details reported in retrospective studies of patients with ABPA included in this scoping review †, interpreted as “reason for switch” if switching to another biologic; otherwise, interpreted as “outcome”. ABPA, allergic bronchopulmonary aspergillosis; AE, acute exacerbation; NR, not reported. In the study by Lamothe et al. (17), all 10 patients received at least two biologic agents, and 4 patients underwent three or more sequential biologic treatments. Initial biologics included omalizumab, mepolizumab, and benralizumab, with treatment durations ranging from 2 to 114 months. Reasons for switching most commonly included lack of clinical response or recurrent exacerbations. Eight patients ultimately received dupilumab as a subsequent biologic, with reported clinical response during follow-up of up to 58 months. In the study by Carter et al. (15), all 27 patients switched biologic therapy after more than 6 months of initial treatment. Reported reasons for switching included non-response, adverse events (such as skin reactions, alopecia, infections, polymyositis, or mental health-related issues), and unstable treatment response. Eleven patients underwent three sequential switches, of whom two patients experienced a fourth switch. Subsequent treatment with dupilumab or tezepelumab was reported in patients previously treated with anti-IgE or anti-IL-5/IL-5R agents, with clinical outcomes documented during follow-up. Across both retrospective cohorts, biologic switching was frequently observed following treatment failure or intolerance to anti-IgE and/or anti-IL-5/IL-5R therapies, while a subset of patients discontinued biologic therapy entirely because of persistent non-response, adverse events, malignancy, or inability to assess treatment effect. Case series studies Three case series (two full-text articles and one conference abstract) reported 8 patients with confirmed ABPA who underwent biologic switching (Table 2). Table 2Therapeutic details reported in case series of patients with ABPA included in this scoping reviewStudyDesignCase numberFirst-line biologicDuration (months)Reason for switchSecond-line biologicDuration (months)OutcomeO'Reilly, A et al. (18)Case series, article1Omalizumab6Responded but switched to reduce inject frequencyBenralizumab18Responded2Omalizumab5Responded but switched to reduce inject frequencyBenralizumab12Responded3Omalizumab26Partially responded but switched to reduce inject frequencyBenralizumab24RespondedKatran, ZY et al. (19)†Case series, article1Omalizumab32No responseMepolizumab12Responded2Omalizumab12No responseMepolizumab12Responded3Omalizumab12No responseMepolizumab13RespondedLamothe, P et al. (20)‡Case series, conference abstract1MepolizumabNRFailed treatment: no response + AEDupilumab32Responded2MepolizumabNRFailed treatment: no response + AEDupilumab58Responded†, one case was excluded because the reported information did not meet the diagnostic criteria for ABPA; ‡, one patient from a duplicate case report and one case with unclear biologic switching details were excluded. ABPA, allergic bronchopulmonary aspergillosis; AE, acute exacerbation; NR, not reported. Therapeutic details reported in case series of patients with ABPA included in this scoping review †, one case was excluded because the reported information did not meet the diagnostic criteria for ABPA; ‡, one patient from a duplicate case report and one case with unclear biologic switching details were excluded. ABPA, allergic bronchopulmonary aspergillosis; AE, acute exacerbation; NR, not reported. In the case series by O’Reilly et al. (18), three patients initially received omalizumab for 5–26 months. Two patients showed clinical response and one partial response, but all switched therapy for treatment-strategy reasons related to injection frequency. All three patients subsequently received benralizumab for 12–24 months, with reported clinical improvement. In the case series by Katran and Bulut (19), three patients initially treated with omalizumab for 12–32 months showed no clinical response and were switched to mepolizumab. Clinical improvement was reported in all patients during 12–13 months of follow-up. In a conference abstract by Lamothe et al. (20), two patients initially treated with mepolizumab discontinued therapy because of lack of efficacy and adverse events and were subsequently switched to dupilumab. Both patients were reported to have sustained clinical response during follow-up of 32 and 58 months, respectively. Case reports and letters A total of 28 individual cases describing biologic switching were identified from case reports, letters, and conference abstracts (11,21-35). Most patients were diagnosed with ABPA, with one case of ABPA complicated by invasive pulmonary aspergillosis. Asthma was the most frequently reported comorbidity, while CF, COPD, and bronchiectasis were reported in a minority of cases. There were 18 females (72.0%) and 7 males (28.0%), with ages ranging from 42 to 83 years. An additional three cases had missing sex and age information (Table 3). Table 3Therapeutic details reported in case reports of patients with ABPA included in this scoping reviewCase report referenceTypeGenderAge (years)DiagnosisComorbiditiesFirst-line biologicDuration (months)Reason for switchSecond-line biologicDuration (months)Outcome/reason for switch†Third-line biologicDuration (months)OutcomeHirota, S et al. (21)ArticleF56ABPAAsthmaOmalizumab23No radiological improvementMepolizumab14RespondedBernal-Rubio, L et al. (22)ArticleM67ABPAAsthmaOmalizumab6No responseBenralizumab4Mümmler, C et al. (23)ArticleF49ABPAAsthmaBenralizumab6No responseOmalizumab5No responseDupilumab4RespondedAli, M et al. (24)ArticleF60ABPACF possibleOmalizumabNRHypersensitivity reactionDupilumab4RespondedBoyle, M et al. (25)ArticleF43ABPACF, asthmaOmalizumabNRAdverse effectsMepolizumab20RespondedMikura, S et al. (26)ArticleM45ABPAAsthmaMepolizumab5AEDupilumab12RespondedKai, Y et al. (27)ArticleF81ABPAAsthmaMepolizumab3AEDupilumab5RespondedAlaga, A et al. (28)ArticleF65ABPAAsthmaOmalizumab1 doseHypersensitivity reactionBenralizumab6RespondedKotetsu, Y et al. (29)ArticleF68ABPAAsthmaBenralizumab2No responseDupilumabNRRespondedOgata, H et al. (11)ArticleM82ABPAAsthmaMepolizumab15AETezepelumab3RespondedHamakawa, M et al. (30)ArticleF83ABPAAsthmaBenralizumab3AEDupilumab0.5RespondedKawasaki, Y et al. (31)ArticleF67ABPAAsthmaMepolizumab24AEDupilumab3RespondedZhao, T et al. (32)ArticleF73ABPA complicated by IPACOPD, asthma and BEOmalizumab4Persistently elevated serum IgEDupilumabNRRespondedRamonell, RP et al. (33)LetterF60ABPAAsthmaOmalizumabNRNo ResponseMepolizumabNRAEDupilumab4RespondedF42ABPAAsthmaMepolizumabNRNo ResponseDupilumab3RespondedTomomatsu, K et al. (34)LetterM61ABPAAsthmaMepolizumab24No radiological improvementBenralizumab20RespondedF69ABPAAsthmaMepolizumab8No radiological improvementBenralizumab18RespondedKubenr, P et al. (35)AbstractF58ABPAAsthmaOmalizumabNRNo ResponseMepolizumab3RespondedWoods, J et al. (36)AbstractM59ABPABronchiolitisOmalizumab4Failed corticosteroid taperingMepolizumabNRNRNugent, MJ et al. (37)AbstractNRNRABPAAsthmaBenralizumabNRIntoleranceDupilumab3RespondedAlvarez-Puebla, MJ et al. (38)AbstractM58ABPAAsthmaOmalizumab24AEBenralizumab6RespondedOshikata, C et al. (39)AbstractF49ABPAAsthmaOmalizumab26Sustained eosinophiliaMepolizumab12AEBenralizumab24RespondedGarcia Vila, H et al. (40)AbstractF54ABPANROmalizumab2 dosesAdverse effectsBenralizumabNRPulmonary infectionPenalver de la Puente, E et al. (41)AbstractNRNRABPAAsthmaOmalizumab12No responseMepolizumab62RespondedHughes, K et al. (42)AbstractF45ABPAAsthmaOmalizumab6Adverse effectsTezepelumab3RespondedShah, S et al. (43)AbstractF68ABPAAsthmaOmalizumabNRFailed corticosteroid taperingDupilumab5Psoriasis with arthralgiaHo, H et al. (44)AbstractNRNRABPANRBenralizumabNRPulmonary infectionOmalizumabNRNRMcGregor, A et al. (45)AbstractM47ABPAAsthmaBenralizumab18AEDupilumabNRResponded†, interpreted as “reason for switch” if switching to another biologic; otherwise, interpreted as “outcome”. ABPA, allergic bronchopulmonary aspergillosis; AE, acute exacerbation; BE, bronchiectasis; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; F, female; IgE, immunoglobulin E; IPA, invasive pulmonary aspergillosis; M, male; NR, not reported. Therapeutic details reported in case reports of patients with ABPA included in this scoping review †, interpreted as “reason for switch” if switching to another biologic; otherwise, interpreted as “outcome”. ABPA, allergic bronchopulmonary aspergillosis; AE, acute exacerbation; BE, bronchiectasis; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; F, female; IgE, immunoglobulin E; IPA, invasive pulmonary aspergillosis; M, male; NR, not reported. Omalizumab was the most commonly reported initial biologic agent (n=15), followed by mepolizumab (n=7) and benralizumab (n=6). Reported reasons for switching included lack of clinical or radiological response, adverse events or intolerance, persistently abnormal inflammatory biomarkers, and failure of corticosteroid tapering. Some patients discontinued initial therapy shortly after initiation because of hypersensitivity reactions. Following biologic switching, clinical outcomes were reported after second- or third-line biologic therapy in most cases. Frequently described switching pathways included transitions from omalizumab to anti-IL-5/IL-5R agents, and from anti-IL-5/IL-5R agents to dupilumab. Several reports described clinical improvement after multiple sequential biologic therapies, although outcome definitions and follow-up durations varied substantially across reports. Summary of biologic switching patterns and reasons A total of 73 published patients with ABPA were reported to undergo biologic switching, accounting for 108 distinct switching events. Omalizumab was the most common first-line biologic, used in 48 patients, followed by mepolizumab (17 patients) and benralizumab (7 patients). The most frequent initial switching pathway was from omalizumab to anti-IL-5/IL-5R therapy, particularly mepolizumab (20 patients) and benralizumab (11 patients). Among patients requiring further switching, transition from anti-IL-5/IL-5R therapy to dupilumab was most commonly reported (15 patients), whereas switching within the same biologic class or returning to anti-IgE therapy was less frequent (Figure 2). Reasons for switching were explicitly reported for 94 of 108 switching events. Inadequate clinical response accounted for 51 events (54.3%), followed by adverse events or intolerance in 27 events (28.7%). Corticosteroid-related or biomarker-driven concerns contributed to 11 events (11.7%), while other treatment-related considerations accounted for 5 events (5.3%). As multiple switching events were reported in individual patients, these events should not be interpreted as independent observations. Sankey diagram of biologic switching in allergic bronchopulmonary aspergillosis. Sankey diagram summarizing reported biologic switching pathways in patients with ABPA. Each column represents a line of biologic therapy, and flows indicate transitions between biologic agents. Numbers (n) denote the frequency of reported switching events. ABPA, allergic bronchopulmonary aspergillosis. Discussion This scoping review systematically summarizes the existing evidence on biologic switching in patients with ABPA. Several key observations emerge from the available literature. First, although biologic therapy in ABPA is largely supported by case-based evidence, switching between biologic agents is frequently reported in clinical practice, reflecting heterogeneous treatment responses and tolerability profiles. Second, across retrospective cohorts, case series, and individual case reports, clinical improvement was commonly observed after switching to an alternative biologic, even in patients who had failed one or more prior agents. Third, omalizumab was the most frequently used initial biologic, whereas dupilumab was often reported as a subsequent-line therapy associated with clinical improvement, particularly after inadequate response or intolerance to anti-IgE or anti-IL-5/IL-5R agents. Together, these findings suggest that biologic switching represents a pragmatic management strategy in selected patients with refractory or biologic-intolerant ABPA, although the overall quality of evidence remains limited and predominantly descriptive. ABPA is characterized by a dominant T2 inflammatory milieu, in which IL-4-, IL-5-, and IL-13-driven pathways contribute to IgE production, eosinophilic inflammation, mucus plugging, and progressive airway remodeling (3,46). Biologic agents currently used off-label in ABPA target distinct components of this inflammatory cascade. Omalizumab, an anti-IgE monoclonal antibody, has been the most extensively reported biologic in ABPA and is often selected based on its established role in allergic asthma (12,47). Anti-IL-5 and anti-IL-5R agents (mepolizumab, reslizumab, and benralizumab) primarily suppress eosinophilic inflammation and have demonstrated benefit in selected ABPA cases (10,48,49). More recently, dupilumab, which blocks the IL-4 receptor α and thereby inhibits both IL-4 and IL-13 signaling, as well as tezepelumab, targeting TSLP, have emerged as alternative options in refractory disease (11,17,24). The observed tendency toward clinical improvement after biologic switching—particularly following transition to dupilumab—raises important mechanistic considerations. Compared with anti-IgE or anti-IL-5/IL-5R therapies, dupilumab provides broader upstream inhibition of T2 inflammatory pathways involved in IgE class switching, mucus hypersecretion, airway remodeling, and fungal-driven allergic inflammation (50). In line with this mechanism, the phase 2 LIBERTY ABPA AIRED study demonstrated that dupilumab improved lung function, reduced severe respiratory exacerbations, and improved health-related quality of life compared with placebo in patients with asthma meeting clinical criteria for ABPA (51). Although this randomized trial did not evaluate biologic switching, it provides higher-level evidence that upstream IL-4/IL-13 pathway blockade can be effective in asthma-associated ABPA. These findings complement, but do not validate, the predominantly case-based switching literature summarized in this review. Nevertheless, the interpretation of these observations requires caution. ABPA is a heterogeneous disorder, and persistent mucus plugging, fungal burden, and established structural airway disease may limit the efficacy of biologics targeting a single inflammatory axis. The apparent benefit observed after switching to biologics with broader immunological coverage may therefore reflect disease phenotype, prior treatment exposure, or reporting bias rather than true comparative superiority. Several limitations of this scoping review should be acknowledged. The overall quality of evidence is low, with most data derived from retrospective studies, small case series, and individual case reports, many of which lack standardized outcome definitions, uniform follow-up durations, or objective response criteria. Publication bias is likely, as cases with favorable responses are more likely to be reported. In addition, heterogeneity in patient populations—including differences in comorbid asthma severity, CF status, extent of bronchiectasis, and background antifungal or corticosteroid use—limits the generalizability of the findings. Finally, the timing and duration of biologic therapy and switching strategies were highly variable, precluding meaningful assessment of optimal treatment sequencing or washout intervals. As a scoping review, this study was designed to map the existing evidence rather than to perform quantitative synthesis, and no conclusions regarding comparative efficacy can be drawn. Important knowledge gaps remain, including the optimal duration of biologic therapy in ABPA and the lack of validated biomarkers to guide biologic selection, switching, or discontinuation. Further mechanistic studies and prospective comparative trials are needed to clarify the role of different inflammatory pathways across ABPA phenotypes and to inform evidence-based biologic treatment strategies. Conclusions This scoping review demonstrates that biologic switching is a common and clinically relevant strategy in the management of ABPA, particularly in patients who are refractory to or intolerant of initial biologic therapy. Across published clinical reports, switching between biologics was frequently associated with clinical improvement, with omalizumab most often used as first-line therapy and dupilumab frequently reported as a subsequent-line option associated with clinical improvement. These findings highlight the heterogeneity of treatment response in ABPA and the current lack of evidence-based guidance for biologic selection and sequencing. Until comparative randomized trials become available, accumulated published clinical reports evidence from biologic switching cases may help inform individualized clinical decision-making in refractory ABPA. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Reporting Checklist: The authors have completed the PRISMA-ScR reporting checklist. Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0641/rc Funding: This work was supported by Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University (No. GCC2025008), Clinical & Basic Science Technology Innovation Project of Guangdong Medical University (No. GDMULCJC2025116), and Guangdong Medical Scientific Research Found (No. A2025060). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0641/coif). R.C. serves as an unpaid editorial board member of Journal of Thoracic Disease. All authors report receiving support from Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University, Clinical & Basic Science Technology Innovation Project of Guangdong Medical University, and Guangdong Medical Scientific Research Found. The authors have no other conflicts of interest to declare. References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0641/prf Supplementary Materials The article’s supplementary files as